OTC Device Claims For COPD ‘Therapy’ Put Patients At Risk – UK Regulator
Executive Summary
ASA finds device marketer BioLife Solutions could not rely on a disclaimer and use of the word “therapy” instead of “treatment” to offset the message its Airnergy device treats a medical condition. ASA advices not to make COPD treatment claims unless a product is properly certified.
You may also be interested in...
UK Homeopathic Energy 'Balance' Claims Tilt Consumers Toward Trouble
UK regulator tells Natural Healing Solutions to discontinue online claims its products are “programmed” with resonance patterns to read energy levels and prevent disease. In a ruling published April 19, the agency noted the company acknowledged receipt of the complaint, but did not respond.
Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction
House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.